2025
An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts.
Zeidan A, Griffiths E, Dinardo C, Mannis G, Montesinos P, Arnan M, Savona M, Odenike O, McCloskey J, Amin H, Fathi A, Bernal del Castillo T, Rodriguez-Macias G, Liesveld J, Im A, Oganesian A, Xu Q, Dijkstra M, Keer H, Roboz G. An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts. Journal Of Clinical Oncology 2025, 43: 6504-6504. DOI: 10.1200/jco.2025.43.16_suppl.6504.Peer-Reviewed Original ResearchAcute myeloid leukemiaAll-oral regimenInduction chemotherapyEuropean LeukemiaNetCR rateMedian time to CRTreatment-emergent adverse eventsBCL-2 inhibitor venetoclaxDiagnosed AMLDiagnosed acute myeloid leukemiaMedian CR durationPhase 2 partAll-oral regimensIntensive induction chemotherapyPhase 1/2 trialBone marrow examinationMedian Follow-UpTime to CRConfidence intervalsDrug-drug interactionsPhase 2 cohortIntravenous decitabineMedian OSCR durationFebrile neutropenia
2019
Durability of complete response (CR) with atezolizumab (atezo) in locally advanced/metastatic urothelial carcinoma (mUC).
Loriot Y, Balar A, Dreicer R, Hoffman-Censits J, Perez-Gracia J, Petrylak D, Van Der Heijden M, Shen X, Zhu Q, Ding B, Kaiser C, Rosenberg J. Durability of complete response (CR) with atezolizumab (atezo) in locally advanced/metastatic urothelial carcinoma (mUC). Journal Of Clinical Oncology 2019, 37: 4527-4527. DOI: 10.1200/jco.2019.37.15_suppl.4527.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply